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(78.8%), retinopathy (27.9%) and nephropathy (22.2%); Indian were highest in PVD 
(26.8%), and CAD (34.4%); Chinese highest in stroke (12.1%). After adjusting for 
age, gender and ethnicity, the odds of having “optimal” glycemic control was higher 
for T2DM patients with nephropathy (Adj OR:1.50; 95% CI [1.19–1.89]) and stroke 
(Adj OR:1.51; 95% CI [1.17–1.96]) compared to PVD (Adj OR: 0.61; 95% CI 
[0.51–0.74]) and retinopathy (Adj OR: 0.65; 95% CI [0.53–0.79]). CONCLUSIONS: 
There were ethnic differences in the prevalence of diabetes-related complications. 
T2DM patients with stroke or nephropathy were more likely to achieve “optimal” 
HbA1c level than those with PVD or eye complications. 
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OBJECTIVES: Health technology Assessment (HTA) has a long history in Australia and 
NZ and is rapidly evolving in Asian countries. The aim of this research was to identify 
and review English written reports on diabetes among HTA agencies in Asia and 
Oceania. METHODS: ISPORs directory (http://www.ispor.org) listing worldwide HTA 
organizations were searched for agencies in Asia and Oceania with a valid link to a 
webpage were included. On each agencies webpage a search was done using the search 
term “diabetes” and English written assessments were included for further review. 
RESULTS: The following HTA agencies were searched: PBAC, MSAC ASERNIP-S, 
AHTA, CCE, CHERE, HTA, NIPH, CRECON, MAPI, PHIC, PKEBM, ICTACH, 
HSAC, NZHTA, HIRA, CDE and HITAP. Of those, only 14 relevant reports were 
found from Australia, NZ and Thailand. Two were found from PBAC, ﬁ ve from AHTA, 
one from HSAC, two from NZHTA, and four from HITAP. The two reports from PBAC 
were describing how to improve National management of diabetes. The reports from 
AHTA were horizon scanning reports covering glucose monitoring, screening of gesta-
tional diabetes and detecting retinopathy. HSAC had a report on insulin pump whereas 
as NZHTA had one on glucose monitoring and one about clinical features detecting 
insulin resistance. The reports found on HITAP were in the form of published articles 
assessing cost effectiveness of two different antihypertensive therapies in diabetes, one 
assessing cost effectiveness of diabetes management and ﬁ nally one assessing diabetes 
self management. Reports from HSAC, NZHTA and HITAP contained economic 
modeling with QALY as outcome. CONCLUSIONS: Despite of broad search criteria 
only 14 English written reports were found on diabetes. A headline in English on each 
assessment would facilitate information sharing and make it easier to evaluate the need 
for translational support. 
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OBJECTIVES: Due to the effect of National Health Insurance drug price cut policy, 
the studied hospital has changed the manufactures of metformin four times in 5 years 
since July, 2004. The purpose of this study is to investigate the effects of the change 
in hospital drug brands on patients’ utilization and the factors that inﬂ uence patients’ 
persistence on the use of metformin. METHODS: Data were sourced from a medical 
center in Taipei city during 2004–2008. We collected all the oral antidiabetic drugs 
used during the study period and classiﬁ ed them into ﬁ ve categories: Biguanid, Sulfo-
nylures, α-glucosidase inhibitor, Thiazolidinediones, and Meglitinide. The quantity of 
all the antidiabetics used was transformed by using WHO/ATC into DDDs. In this 
study, Metformin was treated as the experimental group and all other antidiabetics 
drugs were the control groups. RESULTS: The results showed that the quantity of 
metformin prescribed was increasing during the study period in spite of the brand 
change. However, other categories of oral antidiabetes were also increasing due to the 
increase in number of patients. The percentage of all types of drug stayed relatively 
steadily, in which metformin itself occupied 21–23%, all Sulfonylureas drugs occupied 
59–60%, α-glucosidase inhibitor occupied 3–4%, Thiazolidinediones occupied 
10–11%, and Meglitinide occupied 4–5% during the study period. In addition, the 
results of logistic regressions showed that female patients with hypertension or hyper-
lipemia between the ages of 40~80 who live in Taipei city performed better persistence 
of seeking medical service. CONCLUSIONS: The results shows changing the brand 
of metformin did not decrease drug consumption and patient numbers. By analyzing 
the acceptance of generic drugs of patients and doctors, this study provides important 
information for hospital administrators and health administrators. 
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OBJECTIVES: To explore current disease status and approach to care for patients 
with type 2 diabetes (T2DM) in China. METHODS: The study was performed using 
data from the Adelphi T2DM Disease Speciﬁ c Programme (DSP©), a cross-sectional 
study of consulting patients providing insights into “real-world” behaviors and atti-
tudes in clinical practice in 2008. The DSP collected data on 1648 patients with T2DM 
receiving at least one oral anti-diabetic with or without insulin and from 200 physi-
cians (140 specialists and 60 internal medicine) across general hospitals in nine 
Chinese cities through physician interviews, patient record forms and patient-
completed questionnaires. RESULTS: Of 1648 patients (50% male, mean [SD] age: 
57.74 [12.56] years, BMI: 24.04 [3.37] kg/m2, duration of diabetes: 4.52 [5.06] years), 
74% had at least one comorbidity, 39% were overweight (24 ≤ BMI < 28 kg/m2) and 
9% were obese (BMI ≥ 28 kg/m2). Sixty-one percent had an HbA1c ≥ 7% and only 
35% of patients were aware of an HbA1c target. 39.20% of patients were treated 
with OAD monotherapy (metformin [Met]: 12.26%, Sulphonyureas [SU]: 12.56%, 
alpha-glucosinase inhibitor [AGI]: 8.37%, prandial glucose regulators [PGR]: 4.67%, 
thiazolidinediones [TZD]: 2.31%) and 29.67% were on dual OAD therapy (com-
monly Met + SU: 11.71%, Met + AGI: 4.37%, SU + AGI: 3.82%, Met + PGR: 4.25%, 
Met + TZD: 1.52%), while 28.09% of patients were on OAD + insulin therapy. Lack 
of gastrointestinal, liver function side effects and hypoglycemia risk, QD dosage, and 
beneﬁ cial effects on blood pressure were the ﬁ ve most cited unmet needs in non-insulin 
diabetes treatment highlighted by physicians. Mean (SD) patient-reported QoL 
(EQ-5D VAS) was 0.86 (0.18) and mean (SD) diabetes treatment satisfaction was 
25.97(5.14)/36 where 0 is very dissatisﬁ ed and 36 very satisﬁ ed. CONCLUSIONS: 
The study population of Chinese T2DM patients is relatively young and recently 
diagnosed. More than half were poorly controlled and the need for further therapeutic 
actions to improve glycemic control as well as better doctor/patient communication 
regarding treatment goals is clear. 
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OBJECTIVES: Examine BMI and achievement of diabetes treatment targets in patients 
with Type 2 Diabetes (T2DM). METHODS: The study used the 2008 Adelphi T2DM 
Disease Speciﬁ c Programme© a cross-sectional study of consulting patients providing 
insights into ‘real-world’ behaviors and attitudes in clinical practice. Data was col-
lected on 1648 patients with T2DM receiving at least one oral anti-diabetic with/
without insulin and 140 specialists and 60 internal medicine physicians distributed 
across general hospitals in nine Chinese cities through physician interviews, patient 
record forms and self-completed questionnaires. RESULTS: Across the 1648 patients 
in the study; mean (SD) age was 57.7 (12.6) years, 46% were ≤2 years from diagnosis 
and mean (SD) BMI was 24.0 (3.4) kg/m2. Nine percent of patients were obese (BMI 
≥ 28 kg/m2), 39% overweight (24 ≤ BMI < 28 kg/m2) and 51% normal/underweight 
(BMI < 24 kg/m2). Prevalence of comorbidities in this population was high; 49% 
reporting hypertension and 42% dyslipidemia (25% patients reported both). Glycemic 
control appeared worse in patients with a higher BMI. Twenty-two percent of patients 
with a BMI ≥ 28 had an HbA1c ≥ 9% and 39% had an HbA1c ≥ 8% compared to 
10% of patients with a BMI between 19–27.9 having an HbA1c ≥ 9% and 22% 
having an HbA1c ≥ 8%. Only 35% of patients were aware of having an HbA1c target 
set by their physician. Comorbid conditions were more prevalent in overweight and 
obese patients. Among normal weight patients 31% reported no comorbid conditions 
compared to 22% of overweight patients and 17% of obese patients. Prevalence of 
hypertension, dyslipidemia and other macrovascular conditions were 44%, 36%, and 
18% respectively among normal weight patients; 53%, 48%, and 19% among over-
weight patients and 65%, 55%, and 24% among obese patients. CONCLUSIONS: 
The results indicate that obese patients report higher HbA1c and higher rates of 
complications compared to the normal weight patients and strategies to improve target 
better outcomes could include managing obesity. 
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OBJECTIVES: An objective of this review was to assess clinical efﬁ cacy in terms of 
“HBeAg seroconversion” of treatment options for HBeAg-positive chronic hepatitis 
B (CHB). METHODS: A systematic review of randomized controlled trials (RCTs) of 
treatments for patients with HBeAg-positive CHB was performed through the Medline 
and Cochrane databases. The clinical studies were included only if they assessed the 
efﬁ cacy among the following treatment options namely 1) lamivudine; 2) entecavir; 
3) interferon; and 4) interferon plus lamivudine. Indirect or mixed-treatment compari-
son meta-analysis with random effect model was employed to combine results of 
several studies. The meta-analysis was carried out using the WinBUGS14 software. 
Odds ratio (OR) and its 95% conﬁ dence interval (CI) were presented. Heterogeneity 
test was applied for testing the variation of study outcomes between studies. RESULTS: 
There were 115 abstracts reviewed with eight relevant RCTs included in the analysis. 
None of eight RCTs included all four treatment options. Five studies compared HBeAg 
seroconversion between entecavir and lamivudine. There were three different studies 
comparing interferon with interferon plus lamivudine, interferon plus lamivudine with 
lamivudine, and interferon and interferon plus lamivudine with lamivudine. Indirect 
